Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124406846 | 12440684 | 6 | F | 20160719 | 20160824 | 20160606 | 20160826 | EXP | PHHY2016CO053936 | NOVARTIS | 53.01 | YR | M | Y | 60.00000 | KG | 20160826 | CN | COUNTRY NOT SPECIFIED | CO |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124406846 | 12440684 | 1 | PS | TASIGNA | NILOTINIB | 1 | Oral | 2 DF, Q12H | 22068 | 2 | DF | CAPSULE | Q12H | ||||||
| 124406846 | 12440684 | 2 | C | DOPAMINE | DOPAMINEDOPAMINE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 0 | SOLUTION | ||||||||||
| 124406846 | 12440684 | 3 | C | VANCOMYCIN | VANCOMYCIN | 1 | Intravenous (not otherwise specified) | 0 | SOLUTION | ||||||||||
| 124406846 | 12440684 | 4 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 40 MG, Q12H | 0 | 40 | MG | TABLET | Q12H | ||||||
| 124406846 | 12440684 | 5 | C | ALBUMIN | ALBUMIN HUMAN | 1 | Intravenous (not otherwise specified) | 0 | SOLUTION | ||||||||||
| 124406846 | 12440684 | 6 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 20 MG, Q12H | 0 | 20 | MG | CAPSULE | Q12H | ||||||
| 124406846 | 12440684 | 7 | C | ESOMEPRAZOLE | ESOMEPRAZOLE | 1 | Oral | 40 MG, QD | 0 | 40 | MG | CAPSULE | QD | ||||||
| 124406846 | 12440684 | 8 | C | ENSURE | AMINO ACIDSDEXTROSEELECTROLYTES NOSSOYBEAN OILVITAMINS | 1 | Unknown | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124406846 | 12440684 | 1 | Chronic myeloid leukaemia |
| 124406846 | 12440684 | 2 | Product used for unknown indication |
| 124406846 | 12440684 | 3 | Product used for unknown indication |
| 124406846 | 12440684 | 4 | Product used for unknown indication |
| 124406846 | 12440684 | 5 | Product used for unknown indication |
| 124406846 | 12440684 | 6 | Product used for unknown indication |
| 124406846 | 12440684 | 7 | Product used for unknown indication |
| 124406846 | 12440684 | 8 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124406846 | 12440684 | DE |
| 124406846 | 12440684 | HO |
| 124406846 | 12440684 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124406846 | 12440684 | Abdominal pain | |
| 124406846 | 12440684 | Acute lymphocytic leukaemia | |
| 124406846 | 12440684 | Back pain | |
| 124406846 | 12440684 | Blister rupture | |
| 124406846 | 12440684 | Central nervous system leukaemia | |
| 124406846 | 12440684 | Death | |
| 124406846 | 12440684 | Diarrhoea | |
| 124406846 | 12440684 | Erythema | |
| 124406846 | 12440684 | Fluid retention | |
| 124406846 | 12440684 | Gastritis | |
| 124406846 | 12440684 | Hepatic cirrhosis | |
| 124406846 | 12440684 | Inflammation | |
| 124406846 | 12440684 | Leukaemic infiltration hepatic | |
| 124406846 | 12440684 | Liver disorder | |
| 124406846 | 12440684 | Malaise | |
| 124406846 | 12440684 | Oncologic complication | |
| 124406846 | 12440684 | Second primary malignancy | |
| 124406846 | 12440684 | Swelling |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124406846 | 12440684 | 1 | 20160322 | 0 |